Deficiency in DNA damage repair is commonly found in many cancers [20, 21], however, it remains unclear whether and how this defect may influence the pathological response after cisplatin neoadjuvant chemotherapy in BRCA1-associated TNBCs. This evidence concerns the gene BRCA1 and cancer.